GLP-1 Drugs and Metformin Trim BMI in Obese Youth but Long-Term Safety Remains Unknown
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
Summary
A major Cochrane systematic review analyzed 37 randomized controlled trials involving over 4,200 children and adolescents with obesity. Drugs including GLP-1 receptor agonists, metformin, orlistat, and others reduced BMI by about 1.8 kg/m² and body weight by roughly 5.5 kg compared to placebo. However, the evidence was rated low certainty due to high variability across studies. Adverse events were common but discontinuation rates were only slightly higher with medications. Crucially, quality of life showed little improvement, and data on children under 10 were scarce. The review calls for longer follow-up studies to understand growth impacts, optimal treatment duration, and what happens when these medications are stopped in younger populations.
Detailed Summary
Childhood and adolescent obesity is a growing global health crisis, and clinicians face difficult decisions about when and whether to use pharmacological treatments in young patients whose bodies are still developing. This Cochrane systematic review, commissioned by the WHO, offers the most comprehensive evidence synthesis to date on this question.
Researchers analyzed 37 randomized controlled trials with 4,218 participants, evaluating medications including GLP-1 receptor agonists (such as semaglutide and liraglutide), metformin, orlistat, sibutramine, topiramate, and phentermine-topiramate combinations. Studies were conducted across 26 countries, with follow-up ranging from 6 to 31 months.
Compared to placebo, pharmacological interventions reduced BMI by a mean of 1.80 kg/m² and body weight by 5.47 kg. These changes, while modest, may be clinically meaningful. However, effect sizes varied substantially across drug classes, and overall evidence certainty was rated low due to significant heterogeneity. Adverse events were frequent across all drug groups, though discontinuation rates were only slightly elevated versus placebo. Quality of life, measured by validated questionnaires, showed little to no improvement with treatment.
For children under 10 specifically, data were extremely sparse — only 8 of 37 trials enrolled this age group, and results were rarely disaggregated by age. This is a critical gap given that younger children face different developmental and physiological risks. The long-term consequences of treatment discontinuation, potential effects on growth trajectories, and impact on obesity-related comorbidities beyond weight metrics remain largely unstudied.
The review underscores that while pharmacotherapy can produce measurable weight reductions in obese adolescents, clinicians must weigh these modest gains against incomplete safety data and the absence of demonstrated quality-of-life benefits. Longer, more rigorous trials tracking growth, metabolic health, and psychosocial outcomes are urgently needed before broader pediatric prescribing can be confidently recommended.
Key Findings
- Obesity drugs reduced BMI by ~1.8 kg/m² and body weight by ~5.5 kg vs. placebo in adolescents (low-certainty evidence).
- Adverse events were frequent; drug groups showed only slightly higher discontinuation rates than placebo.
- Quality of life showed little to no improvement with pharmacological treatment versus placebo.
- Data on children under 10 are extremely scarce, limiting conclusions for younger age groups.
- Long-term effects on growth, treatment discontinuation outcomes, and comorbidities remain largely unknown.
Methodology
This Cochrane systematic review included 37 RCTs (35 parallel-group, 2 crossover) totaling 4,218 participants aged 0–19 with essential obesity, requiring at least 3 months of treatment and 6 months follow-up. Evidence certainty was assessed using GRADE; risk of bias was evaluated with RoB 2. Meta-analyses used mean differences for continuous outcomes and risk ratios for dichotomous outcomes.
Study Limitations
Evidence certainty is low to very low for most outcomes due to high heterogeneity across trials, and the summary is based on the abstract only, so full subgroup and drug-specific data could not be reviewed. Data for children under 10 are extremely limited, and median follow-up of only 11 months is insufficient to assess long-term growth or developmental impacts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.